Cartesian Therapeutics, Inc.
RNAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | 51.7% | -72.9% | 244.9% | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | -2,731.2% | 100% | 100% | 100% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -7,808.8% | 5,528.5% | -1,884.8% | 1,249% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -7,942.9% | 5,330.9% | -1,610% | 1,350.9% |
| EPS Diluted | -1.38 | 0.6 | -0.68 | -0.069 |
| % Growth | -330% | 188.2% | -885.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |